Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007212 | 0.82 | CA2 (0.42) | CES2CA2CES1 | |
| SCHEMBL8692682 | 0.72 | CA2 (0.47) | CA2 | |
| SCHEMBL739218 | 0.71 | CA2 (0.48) | CES2CA2CES1 | |
| SCHEMBL736191 | 0.71 | CES2 (0.48) | CES2CA2CES1 | |
| SCHEMBL115894 | 0.71 | CES2 (0.48) | CES2CA2CES1 | |
| SCHEMBL115454 | 0.71 | CA2 (0.48) | CES2CA2CES1 | |
| SCHEMBL115897 | 0.71 | CA2 (0.48) | CES2CA2CES1 | |
| Dodecanoate SCHEMBL5520172 | 0.70 | GPR84 (0.50) | — | |
| SCHEMBL3957297 | 0.70 | CPT2 (0.48) | — | |
| SCHEMBL1626363 | 0.70 | CPT2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305142-A1 | CONTACT LENS TREATING SOLUTION | Bausch + Lomb Ireland Limited (IE) | 2024-01-17 | — | — | EP | disclosed |
| EP-4305143-A1 | PRESERVATIVE-FREE CONTACT LENS TREATING SOLUTION | Bausch + Lomb Ireland Limited (IE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022189552-A1 | PRESERVATIVE-FREE CONTACT LENS TREATING SOLUTION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2022-09-15 | — | — | WO | disclosed |
| US-10603382-B2 | Ophthalmic composition | JOHNSON & JOHNSON CONSUMER INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10441658-B2 | Ophthalmic composition | JOHNSON & JOHNSON CONSUMER INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190184016-A1 | OPHTHALMIC COMPOSITION | KENVUE BRANDS LLC | 2019-06-20 | — | — | US | disclosed |
| US-10245324-B2 | Ophthalmic composition | JOHNSON & JOHNSON CONSUMER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180250408-A9 | OPHTHALMIC COMPOSITION | KENVUE BRANDS LLC | 2018-09-06 | — | — | US | disclosed |
| US-9943622-B2 | Minimizing biological lipid deposits on contact lenses | BAUSCH & LOMB INCORPORATED (US) | 2018-04-17 | — | — | US | disclosed |
| US-9884782-B2 | Treatment of glass surfaces for improved adhesion | CORNING INCORPORATED (US) | 2018-02-06 | — | — | US | disclosed |
| US-20090196845-A1 | OPTHALMIC COMPOSITIONS WITH AN AMPHOTERIC SURFACTANT AND AN ANIONIC BIOPOLYMER | SALIX PHARMACEUTICALS, LTD. | 2009-08-06 | — | — | US | disclosed |
| US-20090196846-A1 | OPHTHALMIC COMPOSITIONS WITH AN AMPHOTERIC SURFACTANT AND HYALURONIC ACID | BAUSCH HEALTH AMERICAS, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009097028-A1 | OPHTHALMIC COMPOSITIONS WITH AN AMPHOTERIC SURFACTANT AND HYALURONIC ACID | BAUSCH & LOMB INCORPORATED (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009032433-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A CARBOXYL-MODIFIED FRUCTAN OR A SALT THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090036554-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A TERPENE COMPOUND | BAUSCH & LOMB INCORPORATED | 2009-02-05 | — | — | US | disclosed |
| WO-2009018060-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A TERPENE AND A NATURAL POLYMER | BAUSCH & LOMB INCORPORATED (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036404-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A CARBOXYL-MODIFIED FRUCTAN OR A SALT THEREOF | ISTA PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| WO-2008157140-A1 | OPHTHALMIC COMPOSITION WITH HYALURONIC ACID | BAUSCH & LOMB INCORPORATED (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080311070-A1 | OPHTHALMIC COMPOSITION WITH HYALURONIC ACID | BAUSCH & LOMB INCORPORATED | 2008-12-18 | — | — | US | disclosed |
| US-20080312182-A1 | OPHTHALMIC COMPOSITION WITH HYALURONIC ACID AND POLYMERIC BIGUANIDE | BAUSCH HEALTH US, LLC | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312182-A1 | OPHTHALMIC COMPOSITION WITH HYALURONIC ACID AND POLYMERIC BIGUANIDE | PDE6C, PDE6H, CD44 | CES2 3487/4885CA2 1609/4885CES1 4561/4885 |
| US-20180250408-A9 | OPHTHALMIC COMPOSITION | UACA, HTT, EYA3 | CES2 4867/4885CA2 2252/4885CES1 4612/4885 |
| US-20080311070-A1 | OPHTHALMIC COMPOSITION WITH HYALURONIC ACID | UACA, GLMN, HBG1 | CES2 2920/4885CA2 1550/4885CES1 4563/4885 |
| US-10245324-B2 | Ophthalmic composition | UACA, HTT, EYA3 | CES2 4867/4885CA2 2252/4885CES1 4612/4885 |
| US-20090196845-A1 | OPTHALMIC COMPOSITIONS WITH AN AMPHOTERIC SURFACTANT AND AN ANIONIC BIOPOLYMER | H1-0, H1-2, H1-3 | CES2 2156/4885CA2 220/4885CES1 3419/4885 |
| US-10441658-B2 | Ophthalmic composition | UACA, HTT, EYA3 | CES2 4867/4885CA2 2252/4885CES1 4612/4885 |
| US-20090036554-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A TERPENE COMPOUND | CRYZ, CRYAB, HDAC6 | CES2 4110/4885CA2 2231/4885CES1 3803/4885 |
| US-20090196846-A1 | OPHTHALMIC COMPOSITIONS WITH AN AMPHOTERIC SURFACTANT AND HYALURONIC ACID | H1-0, H1-2, H1-3 | CES2 3599/4885CA2 747/4885CES1 3974/4885 |
| US-20090036404-A1 | OPHTHALMIC COMPOSITIONS COMPRISING A CARBOXYL-MODIFIED FRUCTAN OR A SALT THEREOF | CRYZ, ACMSD, UACA | CES2 3222/4885CA2 113/4885CES1 2183/4885 |
| US-20190184016-A1 | OPHTHALMIC COMPOSITION | UACA, HTT, EYA3 | CES2 4867/4885CA2 2252/4885CES1 4612/4885 |
| US-10603382-B2 | Ophthalmic composition | UACA, HTT, EYA3 | CES2 4867/4885CA2 2252/4885CES1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.